Position in PFE
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$916,701
-$594,536 QoQ
Shares Held
38,069
-29.3% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.48%
of 13F equity value
Holder Rank
#1,376
of 2,821 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Sunpointe, LLC holds $9,495,332 across 8 Drug Manufacturers - General names. PFE ranks #5 (9.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
15,952 | $4,051,329 | |
| 2 | LLY |
ELI LILLY & Co
|
1,268 | $1,520,877 | |
| 3 | ABBV |
AbbVie Inc.
|
4,063 | $1,022,413 | |
| 4 | MRK |
Merck & Co., Inc.
|
7,636 | $981,226 | |
| 5 | PFE |
Pfizer Inc
This page
|
38,069 | $916,701 | |
| 6 | AMGN |
Amgen Inc
|
1,045 | $378,415 | |
| 7 | SNY |
Sanofi
|
7,549 | $322,040 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,393 | $302,331 |
All Filings in PFE
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $916,701 | 38,069 | Shares | Defined | 2026-07-24 | |
| 2026-03-31 | $1,511,237 | 53,819 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $1,657,294 | 66,558 | Shares | Defined | 2026-01-23 | |
| 2025-09-30 | $1,631,866 | 64,045 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $1,312,935 | 54,164 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $234,344 | 9,248 | Shares | Defined | 2025-05-07 | |
| 2024-12-31 | $218,792 | 8,247 | Shares | Defined | 2025-02-03 | |
| 2024-09-30 | $232,446 | 8,032 | Shares | Defined | 2024-10-16 | |
| 2024-06-30 | $228,596 | 8,170 | Shares | Defined | 2024-07-22 | |
| 2024-03-31 | $297,924 | 10,736 | Shares | Defined | 2024-04-15 | |
| 2023-12-31 | $376,976 | 13,094 | Shares | Defined | 2024-02-20 | |
| No filing history on record for this holder in this stock. | ||||||